Precigen Inc
PGEN3.960USD
-0.040-1.00%
收盤 11/11, 16:00（美東）報價延遲15分鐘
1.18B總市值
虧損本益比TTM
關於 Precigen Inc 公司
Precigen, Inc. 是一家專注於發現和臨牀階段的生物製藥公司，致力於推進基因和細胞療法。該公司的專有技術平臺開發的產品候選物旨在針對其核心治療領域（免疫腫瘤學、自身免疫性疾病和傳染病）中的緊急和難治性疾病。該公司已開發出一系列針對多種適應症的療法。該公司通過兩個部門運營：生物製藥和 Exemplar。生物製藥部門主要由公司的法人實體 Precigen 和 ActoBio 以及來自非公司控制的公司的治療和治療平臺的特許權使用費權益組成。Exemplar 部門由 Exemplar Genetics LLC 組成，以 Precigen Exemplar (Exemplar) 的名義開展業務，這是其全資子公司，專注於開發用於醫療保健研究應用的研究模型和服務。
Precigen Inc簡介
公司代碼PGEN
公司名稱Precigen Inc
上市日期Aug 08, 2013
CEODr. Helen Sabzevari, Ph.D.
員工數量143
證券類型Ordinary Share
年結日Aug 08
公司地址20374 Seneca Meadows Parkway
城市GERMANTOWN
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編20876
電話13015569900
網址https://precigen.com/
公司代碼PGEN
上市日期Aug 08, 2013
CEODr. Helen Sabzevari, Ph.D.
Precigen Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.32M
+20.22%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.15M
+12.00%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.14M
+11.34%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
595.77K
+26.11%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
579.24K
+27.13%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
346.07K
-33.50%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
217.84K
+7.39%
Mr. Phil Tennant
Mr. Phil Tennant
Chief Commercial Officer
Chief Commercial Officer
65.03K
+10.16%
Mr. Cesar L. Alvarez
Mr. Cesar L. Alvarez
Independent Director
Independent Director
--
--
Mr. Donald P. Lehr
Mr. Donald P. Lehr
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.32M
+20.22%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.15M
+12.00%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.14M
+11.34%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
595.77K
+26.11%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
579.24K
+27.13%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
346.07K
-33.50%
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Service
781.00K
91.24%
Product
41.00K
4.79%
Other
34.00K
3.97%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
Service
781.00K
91.24%
Product
41.00K
4.79%
Other
34.00K
3.97%
股東統計
更新時間: 10月6日 週一
更新時間: 10月6日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Third Security, LLC
36.47%
Patient Capital Management, LLC
7.50%
Merck Serono SA
5.85%
William H. Miller III Living Trust
4.93%
Adage Capital Management, L.P.
3.20%
其他
42.06%
持股股東
持股股東
佔比
Third Security, LLC
36.47%
Patient Capital Management, LLC
7.50%
Merck Serono SA
5.85%
William H. Miller III Living Trust
4.93%
Adage Capital Management, L.P.
3.20%
其他
42.06%
股東類型
持股股東
佔比
Venture Capital
36.51%
Investment Advisor
15.64%
Individual Investor
7.88%
Corporation
5.85%
Investment Advisor/Hedge Fund
5.14%
Hedge Fund
4.56%
Research Firm
0.97%
Bank and Trust
0.05%
Insurance Company
0.03%
其他
23.37%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
286
222.21M
62.96%
+17.23M
2025Q2
298
229.52M
77.76%
-784.34K
2025Q1
334
228.75M
77.50%
-12.95M
2024Q4
336
223.34M
76.44%
-15.36M
2024Q3
342
222.44M
77.88%
+21.14M
2024Q2
350
183.56M
71.33%
-22.34M
2024Q1
356
187.95M
73.95%
-17.15M
2023Q4
369
187.18M
73.43%
-12.81M
2023Q3
377
185.65M
75.06%
-11.67M
2023Q2
383
181.15M
73.32%
-8.55M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Third Security, LLC
128.72M
36.47%
+12.39M
+10.65%
Sep 17, 2025
Patient Capital Management, LLC
16.27M
4.61%
-1.10M
-6.35%
Jun 30, 2025
Merck Serono SA
20.65M
5.85%
--
--
Mar 31, 2025
William H. Miller III Living Trust
17.39M
4.93%
+17.39M
--
Jun 26, 2025
Adage Capital Management, L.P.
11.28M
3.2%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
9.83M
2.79%
+271.44K
+2.84%
Jun 30, 2025
The Vanguard Group, Inc.
9.07M
2.57%
+274.07K
+3.12%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.75M
1.06%
+269.58K
+7.75%
Jun 30, 2025
Iridian Asset Management LLC
4.28M
1.21%
-307.15K
-6.70%
Jun 30, 2025
Sabzevari (Helen)
3.32M
0.94%
+557.91K
+20.22%
May 16, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Inspire Small/Mid Cap ESG ETF
0.44%
Invesco Nasdaq Biotechnology ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.1%
SPDR S&P Biotech ETF
0.09%
Vanguard US Momentum Factor ETF
0.09%
iShares Micro-Cap ETF
0.09%
Direxion Daily S&P Biotech Bull 3X Shares
0.05%
iShares Biotechnology ETF
0.05%
iShares Russell 2000 Growth ETF
0.03%
ProShares UltraPro Russell2000
0.02%
查看更多
Inspire Small/Mid Cap ESG ETF
佔比0.44%
Invesco Nasdaq Biotechnology ETF
佔比0.1%
ProShares Ultra Nasdaq Biotechnology
佔比0.1%
SPDR S&P Biotech ETF
佔比0.09%
Vanguard US Momentum Factor ETF
佔比0.09%
iShares Micro-Cap ETF
佔比0.09%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.05%
iShares Biotechnology ETF
佔比0.05%
iShares Russell 2000 Growth ETF
佔比0.03%
ProShares UltraPro Russell2000
佔比0.02%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
